Concord Biotech Limited (NSE:CONCORDBIO)

Market Cap	167.81B
Revenue (ttm)	11.88B
Net Income (ttm)	3.56B
Shares Out	104.62M
EPS (ttm)	34.03
PE Ratio	47.14
Forward PE	37.87
Dividend	10.70 (0.67%)
Ex-Dividend Date	Sep 3, 2025

Volume	305,934
Average Volume	150,190
Open	1,607.20
Previous Close	1,604.10
Day's Range	1,583.80 - 1,681.20
52-Week Range	1,345.00 - 2,664.00
Beta	0.96
RSI	27.62
Earnings Date	Aug 13, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,377
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.